| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/01/2006 | EP1629845A2 Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders |
| 03/01/2006 | EP1629839A1 Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain |
| 03/01/2006 | EP1629010A1 Treatment with anti-vegf antibodies |
| 03/01/2006 | EP1628992A2 Methods of modulating metastasis and skeletal related events resulting from metastases |
| 03/01/2006 | EP1628986A2 Synthesis of high molecular weight iron-saccharidic complexes |
| 03/01/2006 | EP1628683A2 Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine |
| 03/01/2006 | EP1628682A2 Composition comprising a pde4 inhibitor and a pde5 inhibitor |
| 03/01/2006 | EP1628673A1 Pharmaceutical compositions comprising an extract of euphorbia prostrata |
| 03/01/2006 | EP1628671A1 Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases |
| 03/01/2006 | EP1628669A1 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| 03/01/2006 | EP1628667A1 Method for treating diseases using hsp90-inhibiting agents in combination with antimitotics |
| 03/01/2006 | EP1628658A1 Nutritional composition and method of inhibiting smooth muscle cell contraction thereof |
| 03/01/2006 | EP1628657A2 Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes |
| 03/01/2006 | EP1628651A2 Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| 03/01/2006 | EP1628650A1 Compositions for the treatment of reduced blood flow |
| 03/01/2006 | EP1628638A2 Antibiotic composition |
| 03/01/2006 | EP1628631A2 Methods of treating hyperproliferative cell disorders |
| 03/01/2006 | EP1494691A4 Treatment of diseases involving defective gap junctional communication |
| 03/01/2006 | EP1472255B1 Aza-arylpiperazines |
| 03/01/2006 | EP1453523B1 Heparin-containing ophthalmic agent |
| 03/01/2006 | EP1379203B1 Condom with an erectogenic composition |
| 03/01/2006 | EP1347971B1 Thiazolyl inhibitors of tec family tyrosine kinases |
| 03/01/2006 | EP1339399B1 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders |
| 03/01/2006 | EP1333823A4 Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis |
| 03/01/2006 | EP1324774B1 Use of a ppar delta activator for treating inflammatory conditions |
| 03/01/2006 | EP1319007B1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/01/2006 | EP1305636B1 Screening method |
| 03/01/2006 | EP1278520B1 Diaryl piperidyl pyrrole derivatives as antiprotozoal agents |
| 03/01/2006 | EP1244433B1 Use of non-human SHIP2 knock-out mammals |
| 03/01/2006 | EP1133285B1 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state |
| 03/01/2006 | EP1123082B1 Preparations for topical application of substances having antiandrogenic effect |
| 03/01/2006 | EP1098638B1 Use of a glucose uptake enhancer for reducing post-ischemic injury of the heart |
| 03/01/2006 | EP1051168B1 Compositions for facilitating surgical procedures |
| 03/01/2006 | EP1037616B1 COMBINATION OF ALPHA-1-ADRENERGIC ANTAGONISTS AND A CGMP PDEv INHIBITOR FOR THE TREATMENT OF IMPOTENCE |
| 03/01/2006 | EP0969845B1 New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders |
| 03/01/2006 | EP0956506B1 Treatment and diagnosis of cancer |
| 03/01/2006 | EP0840750B1 Ha-2 antigenic peptide |
| 03/01/2006 | EP0783526B1 Growth blocking agents to the vitamin b12 binding sites on transcobalamin ii |
| 03/01/2006 | EP0750507B2 Proteasome regulation of nf-kappa-b activity |
| 03/01/2006 | CN1741821A Compositions for cancer treatment |
| 03/01/2006 | CN1741820A Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 03/01/2006 | CN1741819A Sustained release composition for oral administration of drugs |
| 03/01/2006 | CN1741805A High protein, bowman-birk inhibitor concentrate and process for its manufacture |
| 03/01/2006 | CN1741795A Use of P-glycoprotein inhibitor surfactants at the surface of a colloidal carrier |
| 03/01/2006 | CN1741749A Nutritional compositions |
| 03/01/2006 | CN1739803A Bioactive peptide specific medicine for recurrent late phase cancer |
| 03/01/2006 | CN1739496A Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders |
| 03/01/2006 | CN1739492A Electrostatic self-assembly process of preparing multiple medicine controlled releasing coating in exponential increase characteristic |
| 03/01/2006 | CN1739491A Nanometer fiber slow-releasing system and its prepn process and application |
| 03/01/2006 | CN1243770C Neurotrophic growth factor |
| 03/01/2006 | CN1243751C Piperidine compounds as anti-allergic medicine |
| 03/01/2006 | CN1243723C N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors for FSAD |
| 03/01/2006 | CN1243551C Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response |
| 03/01/2006 | CN1243546C Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations |
| 03/01/2006 | CN1243543C Bioimplant formulation |
| 03/01/2006 | CN1243540C Combination of active principles for treating senile dementia such as alzheimer dementia |
| 03/01/2006 | CN1243537C Use of composition containing at least one oxidative sensitive hydrophilic active ingredient through at least one maleic anhydride copolymer stabilization at cosmetic and /or skin |
| 03/01/2006 | CA2479968A1 Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome |
| 02/28/2006 | US7005557 Film-forming compositions for protecting skin from body fluids and articles made therefrom |
| 02/28/2006 | US7005553 such as 2-nitrophenol by reacting 3-hydroxy-4-methoxybenzophenone with alkyl nitrate in presence of regioselective acid catalyst (sulfuric acid) |
| 02/28/2006 | US7005500 Nucleotide sequence coding polypeptide for use in the diagnosis of of neoplastic disorders |
| 02/28/2006 | US7005448 Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma |
| 02/28/2006 | US7005438 Pharmaceutically active isoindoline derivatives |
| 02/28/2006 | US7005425 Administering a minimal dose of an Al adenosine receptor agonist in conjunction with a minimal dose of a beta blocker, calcium channel blocker, or cardiac glycoside |
| 02/28/2006 | US7005424 Admininstering mixtures of anticarcinogenic agents and early genes for prophylaxis of cancer, tumors or metastasis; gene expression inhibitors |
| 02/28/2006 | US7005408 Anhydrous warming, non- toxic and nonirritating lubricating compositions containing polyhydric alcohols and an insulating agent. The invention also relates to methods of using such compositions for lubrication, administration of active |
| 02/28/2006 | US7005274 Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass |
| 02/28/2006 | US7005255 Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| 02/28/2006 | US7005138 Intravaginal or rectal delivery of selected serotonin reuptake inhibitors (ssris); antidepressants, analgesics, treating psychological disorders, pre-menstrual dysphoric disorder and obsessive compulsive disorders |
| 02/28/2006 | US7005122 Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route |
| 02/28/2006 | US7005121 Arerosol; heating drug, vaporization, cooling |
| 02/28/2006 | US7004945 Devices and methods for the restoration of a spinal disc |
| 02/23/2006 | WO2006021008A2 Ionophores as cancer chemotherapeutic agents |
| 02/23/2006 | WO2006019659A1 Use of vitamin ds to treat kidney disease |
| 02/23/2006 | WO2006018997A1 External preparation |
| 02/23/2006 | WO2006018655A1 Use of xenon as neuroprotectant in a neonatal subject |
| 02/23/2006 | WO2006018633A1 Use of gsk-3 inhibitors for the treatment of prostate cancer |
| 02/23/2006 | WO2006018625A2 Peripheral benzodiazepine receptor independent superoxide generation |
| 02/23/2006 | WO2006018088A1 Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders |
| 02/23/2006 | WO2006017994A1 An analgesic pharmaceutical composition |
| 02/23/2006 | WO2006007671A3 Therapeutically combinations |
| 02/23/2006 | WO2005092362A3 Pharmaceutical combined preparation containing a therapeutic protein |
| 02/23/2006 | WO2005069771A3 Small molecule antagonists of bcl-2 family proteins |
| 02/23/2006 | WO2005004988A3 Compositions and methods relating to novel compounds and targets thereof |
| 02/23/2006 | WO2004093814A3 Compositions of a cyclooxygenase-2 selective inhibitor and a sodium channel blocker |
| 02/23/2006 | WO2003047523A3 Raf-mek-erk pathway inhibitors to treat cancer |
| 02/23/2006 | US20060041021 Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists |
| 02/23/2006 | US20060041014 Treatment of male sexual dysfunction |
| 02/23/2006 | US20060040969 Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of P450 isoenzyme 3A4 |
| 02/23/2006 | US20060040907 Triptolide analogs for the treatment of autoimmune and inflammatory disorders |
| 02/23/2006 | US20060040905 Formulation of nefopam and its use in the treatment of pain |
| 02/23/2006 | US20060040903 Methods of use related to xerostomia |
| 02/23/2006 | US20060040876 Modulation of peroxisome proliferator-activated receptors |
| 02/23/2006 | US20060040853 Methods and compositions useful for modulation of angiogenesis using protein kinase Raf and Ras |
| 02/23/2006 | US20060040850 Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase IV activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states |
| 02/23/2006 | US20060040358 IGF-1 receptor interacting proteins |
| 02/23/2006 | US20060040331 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents |
| 02/23/2006 | US20060040313 Human chemokine beta-9 |
| 02/23/2006 | US20060040266 Diagnostics and therapeutics for diseases associated with neuromedin u2 receptor (nmu2) |
| 02/23/2006 | US20060040265 Regulation of novel human asparagine-hydroxylases |